← All indications
Primary Immunodeficiency Diseases
Genetic immunologic deficiency diseases and syndromes due to mutations in genes involved in IMMUNITY generally characterized by an increased susceptibility to infectious diseases. They are often associated with AUTOIMMUNE DISEASE manifestations.
Subtype terms (9)
More specific conditions that are subtypes of Primary Immunodeficiency Diseases in the MeSH hierarchy.
- Ataxia Telangiectasia
31 drugs (28 approved, 3 experimental)
- Bloom Syndrome
- Chediak-Higashi Syndrome
20 drugs (19 approved, 1 experimental)
- Hereditary Complement Deficiency Diseases
1 drug experimental
- Hyper-IgM Immunodeficiency Syndrome
8 drugs (7 approved, 1 experimental)
- Job Syndrome
5 drugs (3 approved, 2 experimental)
- Leukocyte-Adhesion Deficiency Syndrome
10 drugs approved
- Severe Combined Immunodeficiency
42 drugs (27 approved, 15 experimental)
- Wiskott-Aldrich Syndrome
34 drugs (26 approved, 8 experimental)
Drugs by status
Approved for this indication (9)
Phase 4 trials (9)
Phase 3 trials (11)
Phase 2 trials (40)
- vitamin d3
- cmv-specific t-cells
- anti cd45 monoclonal antibody
- bpx-501
- busulfan
- cd3,cd19 depleted hematopoietic stem cells
- tacrolimus
- lymphocyte immune globulin, anti-thymocyte globulin (equine)
- haploidentical mononuclear cells
- hydroxyurea
- Filgrastim
- motexafin gadolinium
- pentostatin
- allogeneic hematopoietic stem cells
- sirolimus
- cyclosporine
- mycophenolate
- cyclophosphamide
- stem cells
- allogeneic lymphocytes
- alemtuzumab
- Anti-thymocyte Globulin (Rabbit)
- bortezomib
- autologous cd34+ cells
- cd45-depleted allogenic peripheral blood stem cell
- ef1αs-ada lentiviral vector transduced patient cd34 cells
- mesna
- fludarabine
- cytotoxic t cells
- thiotepa
- +10 more
Phase 1 trials (6)